PRSS22: A Potential Drug Target and Biomarker (G64063)

Target Name: PRSS22

NCBI ID: G64063

PRSS22

PRSS22: A Potential Drug Target and Biomarker

Protease, serine S1 family member 22 (PRSS22) is a protein that is expressed in various tissues throughout the body. It is a member of the PRSS family, which includes proteins that belong to the serine proteases (Protease-S serine proteases) superfamily. PRSS22 is unique because of its structure and its location in the body.

The PRSS22 protein is a 146-amino acid protein with a calculated molecular mass of 17.9 kDa. It has a single transmembrane domain and a cytoplasmic tail. PRSS22 is also known as PRSS-22 because it is a member of the PRSS family. This family is characterized by the presence of a unique catalytic domain called the serine protease-like domain (SPLD).

The SPLD is a conserved domain that is found in various proteins that belong to the PRSS family. It is composed of a catalytic catalytic acid loop and a carboxyl terminal extension. The SPLD is responsible for the catalytic activity of the PRSS family proteins.

PRSS22 is found in various tissues throughout the body, including the liver, spleen, and pancreas. It is expressed in the liver and spleen, but is not present in the pancreas. The liver and spleen are the primary sites of PRSS22 expression.

PRSS22 has been shown to play a role in the regulation of various cellular processes. For example, it is involved in the degradation of apoptotic cells, which are cells that have reached the end of their lifespan and are no longer able to divide. PRSS22 is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway.

In addition to its role in cellular signaling, PRSS22 may also be a drug target. Its unique structure and location in the body make it an attractive target for small molecules. Furthermore, its involvement in the regulation of cellular processes makes it a potential biomarker for various diseases.

One way to target PRSS22 is to use small molecules that can modulate its activity. These small molecules can interact with the SPLD and the catalytic acid loop to alter the catalytic activity of PRSS22. This can lead to the inhibition of PRSS22-mediated cellular processes, such as the degradation of apoptotic cells.

Another approach to targeting PRSS22 is to use antibodies that recognize and label it. This can be done using techniques such as affinity purification or immunoprecipitation. Once labeled, the antibodies can be used to either activate or inhibit PRSS22-mediated cellular processes.

In conclusion, PRSS22 is a unique protein that is expressed in various tissues throughout the body. Its involvement in the regulation of cellular processes makes it an attractive target for small molecules and antibodies. Its potential as a drug target and biomarker makes it an important area of research.

Protein Name: Serine Protease 22

Functions: Preferentially cleaves the synthetic substrate H-D-Leu-Thr-Arg-pNA compared to tosyl-Gly-Pro-Arg-pNA

The "PRSS22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRSS22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets